# A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions

> **NCT02201316** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 18 (actual)

## Conditions studied

- Gastritis

## Interventions

- **DRUG:** Reference mosapride citrate (GASMOTIN)
- **DRUG:** GR107719B (Formulation 1)
- **DRUG:** GR107719B (Formulation 2)

## Key facts

- **NCT ID:** NCT02201316
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-03
- **Primary completion:** 2014-03-18
- **Final completion:** 2014-03-18
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02201316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02201316, "A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02201316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*